| WHO Approves Deadly H1N1 Arepanrix
Vaccine For Use In Other Countries
Drug giant GlaxoSmithKline says its Arepanrix H1N1 vaccine has
been certified by the World Health Organization (WHO), making
it available for donors to buy for developing countries.
In a statement issued Tuesday, GlaxoSmithKline PLC said WHO had
approved its Canadian Arepanrix
vaccine after examining its quality and safety data. The vaccine
contains the AS03 adjuvant system, a group of chemical compounds
including the neurotoxin squalene.
Last month, Glaxo advised health authorities not to use one batch
of its Canadian-manufactured swine flu vaccine because it triggered
life-threatening side effects like anaphylactic shock.
Canada recently recalled
172,000 doses of the Arepanrix vaccine after 200 deaths and
36 severe allergic reactions.
Several vaccine makers have promised WHO 156 million doses of
swine flu vaccine, which it hopes to start shipping to 95 poor
countries this month.
*
A full list of h1n1 vaccine ingredients, alerts and warnings.
Reference Sources 102
December 1, 2009
 ...............................................................................................................
|
